InterMune to Release Second Quarter Financial Results on July 28
BRISBANE, Calif., July 12 /PRNewswire-FirstCall/ — InterMune, Inc. today announced that it will release second quarter 2005 financial results on Thursday, July 28, 2005 at 4:00 p.m. EDT. The Company will host a live conference call and webcast at 4:30 p.m. EDT that same day.
To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international). To access the webcast, please log on to the Company’s website at http://www.intermune.com/ at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for ten business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 7739311.
About InterMune
InterMune is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. In addition to the currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, three-times-a-week Infergen(R) (interferon alfacon-1), InterMune has a broad and deep late-stage product portfolio addressing HCV infections, particularly nonresponders, or those patients who do not respond to first-line therapy, and idiopathic pulmonary fibrosis (IPF). Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen plus ribavirin, and a Phase IIb trial of daily Infergen plus Actimmune(R) (interferon gamma-1b) with and without ribavirin for the treatment of HCV patients who do not respond to first-line therapy. In addition, InterMune has an early stage small molecule program targeted at the HCV protease. The pulmonology portfolio includes pirfenidone and Actimmune. Pirfenidone is being developed for the treatment of IPF. Actimmune is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF. For additional information about InterMune and its development pipeline, please visit http://www.intermune.com/.
InterMune, Inc.
CONTACT: investors, Judy Hayes of InterMune, Inc., +1-415-466-2242, orir@intermune.com; or media, Carolyn Bumgardner Wang of WeissComm Partners,+1-415-946-1065, or carolyn@weisscommpartners.com, for InterMune, Inc.
Web site: http://www.intermune.com/